185 related articles for article (PubMed ID: 15049639)
21. Synthesis and biological activity of potent HIV-1 protease inhibitors based on Phe-Pro dihydroxyethylene isosteres.
Benedetti F; Berti F; Budal S; Campaner P; Dinon F; Tossi A; Argirova R; Genova P; Atanassov V; Hinkov A
J Med Chem; 2012 Apr; 55(8):3900-10. PubMed ID: 22458611
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.
Sherrill RG; Furfine ES; Hazen RJ; Miller JF; Reynolds DJ; Sammond DM; Spaltenstein A; Wheelan P; Wright LL
Bioorg Med Chem Lett; 2005 Aug; 15(15):3560-4. PubMed ID: 15975788
[TBL] [Abstract][Full Text] [Related]
23. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
Kim RM; Rouse EA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Emini EA; Tata JR
Bioorg Med Chem Lett; 2004 Sep; 14(18):4651-4. PubMed ID: 15324882
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.
Lu D; Vince R
Bioorg Med Chem Lett; 2007 Oct; 17(20):5614-9. PubMed ID: 17822899
[TBL] [Abstract][Full Text] [Related]
25. High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations.
Wannberg J; Kaiser NF; Vrang L; Samuelsson B; Larhed M; Hallberg A
J Comb Chem; 2005; 7(4):611-7. PubMed ID: 16004505
[TBL] [Abstract][Full Text] [Related]
26. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
[TBL] [Abstract][Full Text] [Related]
27. Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Surleraux DL; de Kock HA; Verschueren WG; Pille GM; Maes LJ; Peeters A; Vendeville S; De Meyer S; Azijn H; Pauwels R; de Bethune MP; King NM; Prabu-Jeyabalan M; Schiffer CA; Wigerinck PB
J Med Chem; 2005 Mar; 48(6):1965-73. PubMed ID: 15771440
[TBL] [Abstract][Full Text] [Related]
28. Indium(III) acetate-catalyzed intermolecular radical addition of organic iodides to electron-deficient alkenes.
Miura K; Tomita M; Ichikawa J; Hosomi A
Org Lett; 2008 Jan; 10(1):133-6. PubMed ID: 18072784
[TBL] [Abstract][Full Text] [Related]
29. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.
Tamiya S; Mardy S; Kavlick MF; Yoshimura K; Mistuya H
J Virol; 2004 Nov; 78(21):12030-40. PubMed ID: 15479842
[TBL] [Abstract][Full Text] [Related]
30. Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists.
Tamamura H; Fujii N
Curr Drug Targets Infect Disord; 2004 Jun; 4(2):103-10. PubMed ID: 15180458
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and biological evaluation of novel 4-hydroxypyrone derivatives as HIV-1 protease inhibitors.
Sun CL; Pang RF; Zhang H; Yang M
Bioorg Med Chem Lett; 2005 Jul; 15(13):3257-62. PubMed ID: 15923115
[TBL] [Abstract][Full Text] [Related]
32. Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes.
Tron GC; Pirali T; Billington RA; Canonico PL; Sorba G; Genazzani AA
Med Res Rev; 2008 Mar; 28(2):278-308. PubMed ID: 17763363
[TBL] [Abstract][Full Text] [Related]
33. Atom transfer cyclization catalyzed by InCl3 via halogen activation.
Cook GR; Hayashi R
Org Lett; 2006 Mar; 8(6):1045-8. PubMed ID: 16524264
[TBL] [Abstract][Full Text] [Related]
34. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3' residue.
Mak CC; Le VD; Lin YC; Elder JH; Wong CH
Bioorg Med Chem Lett; 2001 Jan; 11(2):219-22. PubMed ID: 11206463
[TBL] [Abstract][Full Text] [Related]
36. Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Ginman N; Johansson A; Wallberg H; Larhed M; Samuelsson B; Unge T; Hallberg A
J Med Chem; 2006 Mar; 49(5):1828-32. PubMed ID: 16509598
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of pseudo-symmetric HIV protease inhibitors containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere.
Hidaka K; Kimura T; Hayashi Y; McDaniel KF; Dekhtyar T; Colletti L; Kiso Y
Bioorg Med Chem Lett; 2003 Jan; 13(1):93-6. PubMed ID: 12467624
[TBL] [Abstract][Full Text] [Related]
38. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors.
Lee SG; Chmielewski J
Chem Biol; 2006 Apr; 13(4):421-6. PubMed ID: 16632254
[TBL] [Abstract][Full Text] [Related]
39. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
[TBL] [Abstract][Full Text] [Related]
40. New, potent P1/P2-morpholinone-based HIV-protease inhibitors.
Kazmierski WM; Furfine E; Spaltenstein A; Wright LL
Bioorg Med Chem Lett; 2006 Oct; 16(19):5226-30. PubMed ID: 16904316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
